Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
The Cleveland Clinic
Clinical studies suggest that cholinesterase inhibitors (ChEIs) exert a cognitive benefit with chronic use among MCI and AD patients. Some studies also demonstrate a slight treatment benefit for persons who are APOE 4 positive. We propose to conduct a 24-week, randomized, double-blind, placebo-controlled, parallel group study of the Exelon® \[rivastigmine\] transdermal patch in 120 aMCI patients who have one or both APOE 4 alleles. Our preliminary analyses indicate that aMCI patients, even those who convert to AD, exhibit increased fMRI activation on our semantic memory activation task relative to not at-risk healthy participants and that increasing activation over time correlates with declines on neuropsychological testing. In addition, our preliminary data indicate that ChEI treated aMCI patients demonstrate normalization (i.e. reduction) in the magnitude of task-related neural activation over time relative to an untreated group. Furthermore, changes in fMRI magnitude demonstrated greater sensitivity to cholinergic modulation than changes on neuropsychological testing.
Age
55–85
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Diagnosis of amnestic MCI
In good general health with no diseases expected to interfere with the study
Ability to undergo MRI
Fluent in English
Stable prescription dosages 1 month prior to testing
Carrier of the APOE e4 allele (determined by blood draw at screening visit)
You may not be if
Neurological illness/conditions
Medical illnesses/conditions that may affect brain function
Prior history of use of any cholinesterase inhibitor
Instable or severe cardiovascular disease or asthmatic condition